Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Dr. Stavroula Rakitzi
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02893371CT.gov Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies | — | Terminated | — | — | — |
NCT02562287CT.gov Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder | — | Unknown | — | — | — |
NCT02334904CT.gov Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI | — | Unknown | — | — | — |
NCT02087579CT.gov Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants | — | Completed | — | — | — |
NCT01786239CT.gov Omega-3 Dietary Supplements in Schizophrenia | — | Completed | — | — | — |
NCT01498770CT.gov An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308) | — | Completed | — | — | — |
NCT01739127CT.gov Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI | — | Completed | — | — | — |
NCT02582736CT.gov Antipsychotics and Risk of Hyperglycemic Emergencies | — | Completed | — | — | — |
NCT01181960CT.gov Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations | — | Completed | — | — | — |
NCT02918097CT.gov Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode | — | Completed | — | — | — |
Show 29 more trialsShow fewer
NCT01050582CT.gov A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children | — | Completed | — | — | — |
NCT01878513CT.gov Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis | — | Completed | — | — | — |
NCT00746252CT.gov Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder | — | Terminated | — | — | — |
NCT01000402CT.gov Juvenile Bipolar Disorder Outpatient Program | — | Unknown | — | — | — |
NCT00391222CT.gov A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder | — | Completed | — | — | — |
NCT00205699CT.gov Metabolic Effects of Antipsychotics in Children | — | Completed | — | — | — |
NCT02456454CT.gov Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder | — | Completed | — | — | — |
NCT00221403CT.gov Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders | — | Completed | — | — | — |
NCT00216554CT.gov The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania | — | Completed | — | — | — |
NCT00277654CT.gov Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder | — | Completed | — | — | — |
NCT00246246CT.gov A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder | — | Completed | — | — | — |
NCT00076115CT.gov Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents | — | Completed | — | — | — |
NCT00167479CT.gov A Study of Risperidone Monotherapy in Bipolar Anxiety | — | Completed | — | — | — |
NCT00176202CT.gov Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar | — | Completed | — | — | — |
NCT00294255CT.gov Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania | — | Completed | — | — | — |
NCT00057681CT.gov Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents | — | Completed | — | — | — |
NCT00048802CT.gov Treatment and Outcome of Early Onset Bipolar Disorder | — | Completed | — | — | — |
NCT00034580CT.gov Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder | — | Completed | — | — | — |
NCT00177567CT.gov Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study | — | Completed | — | — | — |
NCT00182013CT.gov Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder | — | Completed | — | — | — |
NCT00249236CT.gov A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder | — | Completed | — | — | — |
NCT00181935CT.gov Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder | — | Completed | — | — | — |
NCT00253162CT.gov A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol | — | Completed | — | — | — |
NCT00986336CT.gov A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders | — | Completed | — | — | — |
NCT00257075CT.gov A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder | — | Completed | — | — | — |
NCT00399698CT.gov Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. | — | Completed | — | — | — |
NCT00012558CT.gov Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) | — | Completed | — | — | — |
NCT00250367CT.gov A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder. | — | Completed | — | — | — |
NCT00253149CT.gov A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bipolar Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Risperidone (this asset) | Dr. Stavroula Rakitzi | Approved | BB · 71 |
| Asenapine | Dr. Stavroula Rakitzi | P4 | BBB |
| Citalopram | University of Texas Southwestern Medical Center | P4 | BBB |
| Lithium, Elemental | University of Aarhus | P4 | BBB |
| Quetiapine | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Lamotrigine | Johns Hopkins University | P4 | BBB |
| Escitalopram | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Paroxetine | Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital | P4 | BBB |
| Valproic Acid | University of New Mexico | P4 | BBB |
+42 more in the Bipolar Disorder cohort
Other indications for Risperidone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Major Depressive Disorder | — | P4 | BBB · 78 |
| Psychotic Disorder | — | P4 | BBB · 77 |
| Schizoaffective Disorder | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Risperidone in Bipolar Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/risperidone-bipolar-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →